Meeting
2022 ASCO Annual Meeting
Molecular characterization of cancers with ALK gene fusions in nonlung tumors.
Authors
Jin Zhang
Department of Thoracic Surgery,China-Japan Friendship Hospital, Beinjing, China
Jin Zhang , Yushuai Han , Weiran Wang , Mengxiang Xu , Jianhua Zhu , Tonghui Ma
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Tissue-Based Biomarkers
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 3121)
DOI
10.1200/JCO.2022.40.16_suppl.3121
Abstract #
3121
Poster Bd #
113
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Genetic landscape of ALK+ non-small cell lung cancer (NSCLC) patients (pts) and response to ceritinib in ASCEND-1.
First Author: Daniel Shao-Weng Tan
First Author: Gargi D. Basu
Poster
2022 ASCO Annual Meeting
Driver coexistence characteristics of ALK-fusion in Chinese patients with lung cancer.
First Author: Min Gao
Poster
2013 ASCO Annual Meeting
ALK and ROS1 gene rearrangements detected in colorectal cancer (CRC) by fluorescence in situ hybridization (FISH).
First Author: Andrew James Weickhardt